secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001193125-25-243039
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics secures up to $600M via royalty sale and debt facility
----------------------------------------------------------------------------

- DRI Healthcare pays $55M upfront for U.S. revenue rights; up to $300M total tied to VRDN-003 milestones and FDA approval.
- Tiered royalties on veligrotug/VRDN-003 net sales: 7.5% up to $600M, then declining to zero above $2B.
- Hercules Capital provides $300M term loan facility; $50M drawn at close, with tranches up to $300M depending on milestones.
- Loan bears interest at prime+1.45% (floor 8.95%, cap 9.45%), maturity 2030, interest-only through 2029/2030.
- Combined financing strengthens balance sheet for pivotal clinical trials and pre-commercial activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525243039/0001193125-25-243039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525243039/d20179d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-243039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer